Skip to main content
OpenTrials
Completed

NCT Number: NCT01921725

The Clinical Application and Efficacy Verification of an Innovative Carbon Fiber Dressing

The research uses hydrophilic-based dressing (KoCarbonTM) which is developed by Medical Technology Company Limited (Bio-medical Carbon Technology; BCT) to investigate the wound healing effects of activated-carbon-fiber-based wound dressing on different types of wounds.The dressing is composed by three layers. The first layer is a material of polyethylene terephthalate (PET) weave which is great breathable; Second layer, the activated carbon fiber cloth, is as the absorption of excess tissue fluid, bacteria and contaminations. It reduces the smell of wound and restrains the development of bacteria. In addition, activated carbon has features of far-infrared and anion, which promote blood circulation, speed up metabolism and shorten the time of wound healing. The third layer is a polyethlene (PE) film, which touches the wound surface and provides the anti-adhesion effects.

The aim of this study is to investigate how the application of the dressing affects the wound healing conditions on four different types of wounds, including general traumatic wounds, elective surgery wound, diabetes foot ulcer (level 2) and chronic wounds. Due to the characteristics of great fluid absorption and far-infrared features, the hydrophilic-based dressing (KoCarbonTM) is expected to work perfectly on improving the wound repair conditions.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Wounds Wounds and Injuries

Age range

20 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Division of Plastic Surgery, Department of Surgery, China Medical University Hospital, Taichung, Taiwan

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male/Female of any race aged between 20 - 85 years old
  • The subject is willing and able to understand, sign and date the study Informed Consent
  • The subject is able to adhere to the scheduled visits regimen
  • General traumatic wounds: wound length is less than 20 cm, area less than 100 cm2, and depth less than 0.5 cm
  • Elective surgery wound: wound length less than 20 cm, and apply BCT KoCarbon® Hydrophilic Wound Dressing immediately after surgery
  • Diabetes foot ulcer (level 2): wound area is between 0.5 cm x 0.5 cm - 5 cm x 5 cm
  • Chronic wounds: failed to heal for more than 1 month and wound area is between 0.5 cm x 0.5 cm - 10 cm x 10 cm

Exclusion criteria

  • Male/Female of any race aged younger than 20 years old or older than 85 years old
  • Allergy to activated carbon fiber
  • Patients was participating in another clinical trial less than 30 days before participation in this trial
  • Any systemic or local active dermatological disease that might interfere with the evaluation of the surgical site such as eczema, psoriasis, skin cancer, scleroderma, chronic urticarial
  • Taking any medicine containing steroid in the last 3 months
  • With history of cardiovascular diseases, diabetes mellitus, immune system-related diseases, hepatic disease, hematic diseases, renal diseases, and cancer
  • Pregnancy
  • Severe malnutrition
  • fistula or tunnel wounds
  • General traumatic wounds: already been infected, or have accepted other treatments for more than 1 week
  • Elective surgery wound: already been infected, or delayed suture
  • Diabetes foot ulcer (level 2): combined with necrotizing fasciitis or bone and tendon exposure
  • Chronic wounds: combined with necrotizing fasciitis or bone and tendon exposure

Treatment and study plan

hydrophilic-based dressing (KoCarbonTM)

Device

"BCT" Hydrophilic Wound Dressing consists of PET non-woven, activated carbon fiber (ACF) cloth and PE film. The PET non-woven is vapor permeable to allow air exchange for the wound. The absorbent ACF absorbs exudate, bacteria and odor to create an effective barrier. Furthermore, far infrared ray (FIR) emitted from ACF accelerates blood circulation and metabolism to reduce healing period. The PE film helps to minimize wound trauma at dressing changes.

Other names: "BCT" hydrophilic wound dressing

Primary outcomes

  1. The healing percentage

    Time frame: one month

    Photograph of wounds are taken on each visit and pictures are imported to image-analyzing software for the calculation of wound area. And the number of wound area is then transformed to the healing percentage. Healing Percentage N =[(the initial wound area-wound area measured on Day N)/the initial wound area]x100%. N means the number of days counting from the first day initiating this clinical trial.

Secondary outcomes

  1. The healing rate

    Time frame: one month

    Photograph of wounds are taken on each visit and pictures are imported to image-analyzing software for the calculation of wound area. And the number of wound area is then transformed to the healing rate. Healing Rate= healed area/the number of healing days (cm2/day)

Other outcomes

  1. Antibiotics usage

    Time frame: one month

    The dose and frequency of antibiotics usage of each subject during the whole trial will be recorded.

  2. Infection rate

    Time frame: one month

    The occurrence rate of infection among all the subjects will be calculated.

Sponsors and collaborators

Lead sponsor

Bio-medical Carbon Technology Co., Ltd.

Industry

Collaborators

  • China Medical University Hospital

Registry information

Important dates

Study start
2013
Primary completion
2013
First posted
Aug 13, 2013
Registry last updated
Aug 13, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.